Current status and progress of recurrence of retinopathy in prematurity after intravitreal injection with anti-vascular endothelial growth factor drugs / 中华眼底病杂志
Chinese Journal of Ocular Fundus Diseases
; (6): 617-620, 2019.
Article
en Zh
| WPRIM
| ID: wpr-805503
Biblioteca responsable:
WPRO
ABSTRACT
Intravitreal injection of anti-VEGF drugs for the treatment of retinopathy of prematurity(ROP) is a hot topic of research, and it can be used to treat the ROP (Ⅰzone). The current anti-VEGF drugs include bevacizumab, ranibizumab, aflibercept and conbercept, etc. However, in recent years, several studies have confirmed that anti-VEGF drugs have an increased recurrence rate and a longer recurrence time than conventional laser photocoagulation therapy. The follow-up period should be extended and repeated injections may be required. Due to the lack of large-scale prospective clinical studies, the recurrence rate, time window of recurrence, risk factors and treatment methods of various anti-VEGF drugs for ROP are still unclear. Anti-VEGF drugs in the treatment of ROP needs to accumulate more evidence-based medical evidence.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Ocular Fundus Diseases
Año:
2019
Tipo del documento:
Article